Pembrolizumab vs. chemotherapy in the first-line setting of PD-L1 ≥ 50% metastatic non-small cell lung cancer: a real-world cost-effectiveness analysis
Liu B, Parmar A, Luo J, Dai WF, Chan KKW. Eur J Health Econ. 2025; Oct 8 [Epub ahead of print].
Read our publications related to this topic.
ICES scientists are appointed to the ICES Research Program which best fits their interests and, as such, become members of a network of health services researchers from across Ontario.
The ICES website uses cookies. If that’s okay with you, keep on browsing, or learn more about our Privacy Policy.